Angiotensin II increases coronary fibrosis, cardiac hypertrophy and the incidence of myocardial infarctions in ApoE-/-Fbn1C1039G+/-mice.
L
L
Roth
D M
DM
Schrijvers
W
W
Martinet
G R Y
GR
De Meyer
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D001057:Apolipoproteins E / Q000378:metabolism; D050197:Atherosclerosis / Q000378:metabolism*; D006332:Cardiomegaly / Q000378:metabolism*; D004195:Disease Models, Animal; D000071838:Fibrillin-1 / Q000378:metabolism; D051379:Mice; D009203:Myocardial Infarction / Q000378:metabolism*; D009206:Myocardium / Q000473:pathology*; D009929:Organ Size; D010446:Peptide Fragments / Q000378:metabolism; D016896:Treatment Outcome; D054392:Adipokines
D000804:Angiotensin II; D001057:Apolipoproteins E; D000071838:Fibrillin-1; D010446:Peptide Fragments; C000605724:Fbn1 protein, mouse; D054392:Adipokines; C524718:apolipoprotein E (239-252), mouse
Atherosclerosis; blood pressure; cardiac remodelling; mortality; mouse model; plaque vulnerability